Gene transfer using the mature form of VEGF-D reduces neointimal thickening through nitric oxide-dependent mechanism

Gene Therapy

Volumn 12, Issue 12, 2005, Pages 980-987

  Rutanen, J ^a   Turunen, A M ^a   Teittinen, M ^a   Rissanen, T T ^a   Heikura, T ^a   Koponen, J K ^a   Gruchala, M ^a   Inkala, M ^a   Jauhiainen, S ^a   Hiltunen, M O ^a   Turunen, M P ^a   Stacker, S A ^b   Achen, M G ^b   Yla Herttuala S ^a,c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Angioplasty; Arteries; Nitric oxide; Restenosis; Vascular endothelial growth factor

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; VASCULOTROPIN D;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY WALL; ARTICLE; BLOOD VESSEL WALL; CELL COUNT; CONTROLLED STUDY; DRUG RESPONSE; GENE TRANSFER; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RESTENOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; AORTA; AORTIC DISEASES; BALLOON DILATATION; CONSTRICTION, PATHOLOGIC; GENE THERAPY; GENETIC VECTORS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; RABBITS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSDUCTION, GENETIC; TUNICA INTIMA; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

ORYCTOLAGUS CUNICULUS;

EID: 21344445050     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302489     Document Type: Article

References (37)

1. Narins CR, Holmes DRJ, Topol EJ. A call for provisional stenting: the balloon is back!. Circulation 1998; 97: 1298-1305.
2. Zachary I, Mathur A, Yla-Herttuala S, Martin J. Vascular protection: a novel nonangiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2000; 20: 1512-1520.
3. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5: 1359-1364.
4. Hiltunen MO et al. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation 2000; 102: 2262-2268.
5. Laitinen M et al. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther 2000; 11: 263-270.
6. Makinen K et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002; 6: 127-133.
7. Hedman M et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003; 107: 2677-2683.
8. Achen MG et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 1998; 95: 548-553.
9. Stacker SA et al. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem 1999; 274: 32127-32136.
10. Rutanen J et al. Vascular endothelial growth factor-D expression in human atherosclerotic lesions. Cardiovasc Res 2003; 59: 971-979.
11. Hiltunen MO et al. Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods. FASEB J 2000; 14: 2230-2236.
12. Rissanen TT et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 2003; 92: 1098-1106.
13. Rutanen J et al. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 2004; 109: 1029-1035.
14. Bauters C et al. Mechanisms and prevention of restenosis: from experimental models to clinical practice. Cardiovasc Res 1996; 31: 835-846.
15. Asahara T et al. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 1995; 91: 2793-2801.
16. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77: 527-543.
17. Sarkar R, Gordon D, Stanley JC, Webb RC. Dual cell cycle-specific mechanisms mediate the antimitogenic effects of nitric oxide in vascular smooth muscle cells. J Hypertens 1997; 15: 275-283.
18. Yan Z, Hansson GK. Overexpression of inducible nitric oxide synthase by neointimal smooth muscle cells. Circ Res 1998; 82: 21-29.
19. Kumar A, Lindner V. Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol 1997; 17: 2238-2244.
20. Serrano Jr CV et al. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty J Am Coll Cardiol 1997; 29: 1276-1283.
21. Kornowski R et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998; 31: 224-230.
22. Brasen JH et al. Angiogenesis, vascular endothelial growth factor and platelet-derived growth factor-BB expression, iron deposition, and oxidation-specific epitopes in stented human coronary arteries. Arterioscler Thromb Vasc Biol 2001; 21: 1720-1726.
23. Farb A et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002; 105: 2974-2980.
24. Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 1995; 76: 980-986.
25. Tsao PS et al. Nitric oxide regulates monocyte chemotactic protein-1. Circulation 1997; 96: 934-940.
26. De Caterina R et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96: 60-68.
27. Qian H et al. Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-Fed rabbits. Circulation 1999; 99: 2979-2982.
28. Tsakiris DA et al. Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. Atherosclerosis 1999; 142: 193-200.
29. Cipollone F et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 2001; 21: 327-334.
30. Laitinen M et al. Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum Gene Ther 1998; 9: 1481-1486.
31. Leppanen O et al. Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits. Circulation 2004; 109: 1140-1146.
32. Yla-Herttuala S, Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 2003; 9: 694-701.
33. Puumalainen AM et al. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 1998; 9: 1769-1774.
34. Jones MK, Sarfeh IJ, Tarnawski AS. Induction of in vitro angiogenesis in the endothelial-derived cell line, EA hy926, by ethanol is mediated through PKC and MAPK. Biochem Biophys Res Commun 1998; 249: 118-123.
35. Laitinen M et al. Vegf gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries. Hum Gene Ther 1997; 8: 1737-1744.
36. Ylä-Herttuala S et al. Transfer of 15-lipoxygenase gene into rabbit iliac arteries results in the appearance of oxidation-specific lipid-protein adducts characteristic of oxidized low density lipoprotein. J Clin Invest 1995; 95: 2692-2698.
37. Hakkinen T, Karkola K, Yla-Herttuala S. Macrophages, smooth muscle cells, endothelial cells, and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Colocalization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CD16 (Fc gammaRIII). Virchows Arch 2000; 437: 396-405.